Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observational Study Using Personalized Minimal Residual Disease Assay (Signatera) to Evaluate the Kinetics and Detection Rate in Patients with Non-small Cell Lung Cancer

NCT06854939 is registered in ClinicalTrials.gov with National Cancer Center, Japan as lead sponsor.

NCT NCT06854939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06854939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observational Study Using Personalized Minimal Residual Disease Assay (Signatera) to Evaluate the Kinetics and Detection Rate in Patients with Non-small Cell Lung Cancer
Lead sponsor
National Cancer Center, Japan
Phase
Observational
Overall status
Not yet recruiting
Start date
March 1, 2025
Completion date
September 30, 2029
Enrollment
350 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc, stage i, ii, iii